Study of Suzetrigine Compared to Placebo for Pain Relief After Total Hip Replacement Surgery in Adults

What this Trial Is About

Total hip and knee replacements are common and often painful orthopedic surgeries that typically require strong pain relief to help patients move and recover early. Despite using various pain management methods, many patients still depend on opioids, which can cause side effects like sedation, nausea, constipation, and long-term dependency. Researchers are evaluating Suzetrigine, a non-opioid pain medication, to see if it can reduce opioid use and improve recovery after total hip arthroplasty THA. This study is a randomized, placebo-controlled, double-blind trial focused on assessing Suzetrigines impact on postoperative opioid consumption and pain management. Participants undergoing primary total hip arthroplasty will be randomly assigned to receive either Suzetrigine or a placebo. Treatment involves a loading dose given before surgery, followed by Suzetrigine or placebo administered for seven days. Suzetrigine works by selectively blocking pain signals through peripheral sodium channel inhibition, offering a novel approach to pain relief without affecting cognition or motor function. The study also allows the use of rescue medications like acetaminophen and ibuprofen as part of multimodal analgesia. Throughout the study, participants will be closely monitored for opioid use, pain levels using numeric rating scales at various time points up to 12 weeks after surgery, medication adherence, and side effects. The primary outcome measures opioid consumption during the first 48 hours after surgery. Secondary outcomes include pain intensity, opioid-free status, patient satisfaction, pain interference, functional recovery scores, and adverse events. The total study duration spans up to two years, including follow-up assessments to evaluate longer-term effects and safety.

Suzetrigine in Total Hip Arthroplasty